Generics US drugmaker Forest Laboratories (NYSE: FRX) and Janssen Pharmaceutica, a unit of health care giant Johnson & Johnson (NYSE: JNJ), have jointly filed a law suit in the US District Court for the District of Delaware against several companies for infringement of the US patent relating to their antihypertensive Bystolic (nebivol), which they say expires in December 2021, including patent term extension. 15 March 2012